These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
500 related articles for article (PubMed ID: 32774122)
1. Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice. Gašperšič J; Videtič Paska A Biochem Med (Zagreb); 2020 Oct; 30(3):030504. PubMed ID: 32774122 [TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141 [TBL] [Abstract][Full Text] [Related]
3. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results. Hicks JK; Saller J; Wang E; Boyle T; Gray JE Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384 [TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. Bennett CW; Berchem G; Kim YJ; El-Khoury V Oncotarget; 2016 Oct; 7(43):71013-71035. PubMed ID: 27589834 [TBL] [Abstract][Full Text] [Related]
6. Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy. Oellerich M; Schütz E; Beck J; Walson PD Ther Drug Monit; 2019 Apr; 41(2):115-120. PubMed ID: 30883505 [TBL] [Abstract][Full Text] [Related]
7. Strategies for improving detection of circulating tumor DNA using next generation sequencing. Tébar-Martínez R; Martín-Arana J; Gimeno-Valiente F; Tarazona N; Rentero-Garrido P; Cervantes A Cancer Treat Rev; 2023 Sep; 119():102595. PubMed ID: 37390697 [TBL] [Abstract][Full Text] [Related]
8. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637 [TBL] [Abstract][Full Text] [Related]
9. Cell-free DNA diagnostics: current and emerging applications in oncology. Muluhngwi P; Valdes R; Fernandez-Botran R; Burton E; Williams B; Linder MW Pharmacogenomics; 2019 Apr; 20(5):357-380. PubMed ID: 30983510 [TBL] [Abstract][Full Text] [Related]
10. Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas. Meriranta L; Pitkänen E; Leppä S Semin Hematol; 2023 Jul; 60(3):132-141. PubMed ID: 37455222 [TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation. Liu SC World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986 [TBL] [Abstract][Full Text] [Related]
12. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care. Thierry AR Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041 [TBL] [Abstract][Full Text] [Related]
13. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors. Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661 [TBL] [Abstract][Full Text] [Related]
14. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients. Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951 [TBL] [Abstract][Full Text] [Related]
15. Using circulating cell-free DNA to monitor personalized cancer therapy. Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575 [TBL] [Abstract][Full Text] [Related]
16. Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients. Palande V; Raviv Shay D; Frenkel-Morgenstern M J Vis Exp; 2020 Sep; (163):. PubMed ID: 32986022 [TBL] [Abstract][Full Text] [Related]
17. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA. Kockan C; Hach F; Sarrafi I; Bell RH; McConeghy B; Beja K; Haegert A; Wyatt AW; Volik SV; Chi KN; Collins CC; Sahinalp SC Bioinformatics; 2017 Jan; 33(1):26-34. PubMed ID: 27531099 [TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy and its role in an advanced clinical trial for lung cancer. Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770 [TBL] [Abstract][Full Text] [Related]
19. Clinical application of circulating tumor DNA in metastatic cancers. Raei N; Safaralizadeh R; Latifi-Navid S Expert Rev Mol Diagn; 2023; 23(12):1209-1220. PubMed ID: 37797209 [TBL] [Abstract][Full Text] [Related]
20. Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. Stankunaite R; George SL; Gallagher L; Jamal S; Shaikh R; Yuan L; Hughes D; Proszek PZ; Carter P; Pietka G; Heide T; James C; Tari H; Lynn C; Jain N; Portela LR; Rogers T; Vaidya SJ; Chisholm JC; Carceller F; Szychot E; Mandeville H; Angelini P; Jesudason AB; Jackson M; Marshall LV; Gatz SA; Anderson J; Sottoriva A; Chesler L; Hubank M Eur J Cancer; 2022 Feb; 162():209-220. PubMed ID: 34933802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]